1. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment:a post-treatment analysis of a randomised placebo-controlled trial
- Author
-
Jensen, Simon Birk Kjær, Blond, Martin Bæk, Sandsdal, Rasmus Michael, Olsen, Lisa Møller, Juhl, Christian Rimer, Lundgren, Julie Rehné, Janus, Charlotte, Stallknecht, Bente Merete, Holst, Jens Juul, Madsbad, Sten, Torekov, Signe Sørensen, Jensen, Simon Birk Kjær, Blond, Martin Bæk, Sandsdal, Rasmus Michael, Olsen, Lisa Møller, Juhl, Christian Rimer, Lundgren, Julie Rehné, Janus, Charlotte, Stallknecht, Bente Merete, Holst, Jens Juul, Madsbad, Sten, and Torekov, Signe Sørensen
- Abstract
Background: New obesity medications result in large weight losses. However, long-term adherence in a real-world setting is challenging, and termination of obesity medication results in weight regain towards pre-treatment body weight. Therefore, we investigated whether weight loss and improved body composition are sustained better at 1 year after termination of active treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, supervised exercise program, or both combined for 1 year. Methods: We conducted a post-treatment study in extension of a randomised, controlled trial in Copenhagen. Adults with obesity (aged 18–65 years and initial body mass index 32–43 kg/m2) completed an eight-week low-calorie diet-induced weight loss of 13.1 kg (week −8 to 0) and were randomly allocated (1:1:1:1) to one-year weight loss maintenance (week 0–52) with either supervised exercise, the GLP-1 receptor agonist once-daily subcutaneous liraglutide 3.0 mg, the combination of exercise and liraglutide, or placebo. 166 Participants completed the weight loss maintenance phase. All randomised participants were invited to participate in the post-treatment study with outcome assessments one year after treatment termination, at week 104. The primary outcome of the post-treatment assessment was change in body weight from after the initial weight loss (at randomisation, week 0) to one year after treatment termination (week 104) in the intention-to-treat population. The secondary outcome was change in body-fat percentage (week 0–104). The study is registered with EudraCT, 2015-005585-32, and with ClinicalTrials.gov, NCT04122716. Findings: Between Dec 17, 2018, and Dec 17, 2020, 109 participants attended the post-treatment study. From randomisation to one year after termination of combined exercise and liraglutide treatment (week 0–104), participants had reduced body weight (−5.1 kg [95% CI −10.0; −0.2]; P = 0.040) and body-fat percentage (−2.3%-points [−4.3 to −0.3]; P = 0.026)
- Published
- 2024